Podcasts about Hazard

On this week's episode of The One Piece Podcast we go through Volume 112 with Josh McKenzie (contributor and storyboard artist) and special guest Stephen Paul (translator for One Piece in Shonen Jump & Manga Plus)! This week we're also catching up on the latest One Piece collaborations and events, including an exclusive rundown of the One Piece x Dodgers game from our sports correspondent Steve Yurko! SUBSCRIBE TO US ON PATREON! We've opened up a BRAND NEW “Sticker of the Month Club” tier on Patreon that entitles you to a patron-exclusive sticker of one of our amazing episode images every month! You also get access to ad-free episodes and our 800+ episode archive, our exclusive series 4'ced to Watch 4Kids with Steve & Alex, our full-length film OPPJapan, exclusive episodes with our special guests and a lot more. 00:00:00 Introduction;00:34:27 Manga Recap: Volume 112;01:49:49 Trivia & To Be Continued…! NEWS & UPDATES Want to know when One Piece is going to end? So does our man in Japan and OPLA live action series advisor Greg Werner! Check out his column “The End of One Piece,” posted exclusively by the OPP! Our video recording of the OPP at City Winery is now LIVE for patrons! You can watch our previous show from April on YouTube here! The OPP is officially British Famous! Read what Zach had to tell the good people of England about One Piece as it lands on BBC iPlayer in “One Piece: From ‘niche within a niche' to global phenomenon” by Samuel Spencer! OPLA! is back for a whole new season! Check out interviews with the cast including Aidan Scott (Helmeppo), Alexander Maniatis (Kuro), Craig Fairbrass (Zeff) and Chioma Umeala (Nojiko)! Don't miss out, subscribe at patreon.com/onepiecepodcast to get the full One Piece Podcast experience!  We have an all new series about the history of 4Kids … as told by the people who were actually there. Check out 4Kids Flashback every Wednesday! Learn more about your ad choices. Visit megaphone.fm/adchoices

One morning as she arrived for her hospital shift, Winnipeg nurse Jennifer Noone was assaulted outside the staff entrance, leaving her with a bad concussion and PTSD. Rather than stay silent, she took the unusual step of having her assailant charged with assault. Manitoba Nurses Union President Darlene Jackson says there needs to be more and better security and violence should not be accepted as just part of the job.

TRENER SOPIČ JEST Z NAMI BRUTALNIE SZCZERY - MATEUSZ ŻYRO OPOWIADA JAK WYGLĄDA WSPÓŁPRACA Z TRENEREM I JAKIE MA OCZEKIWANIA NA NOWY SEZON WIDZEWA. OCENIA BRATA JAKO EKSPERTA I KOMENTATORA. PO WIĘCEJ ROZWIŃ OPIS_______________________________________________________________⭐️ PARTNEREM KANAŁU JEST LEGALNY POLSKI BUKMACHER LEBULL

Airflow Experts (732-824-8243) offers professional dryer vent and air duct cleaning in Monmouth County. Most homeowners overlook hidden fire hazards—but regular cleanings can improve safety, air quality, and energy efficiency before it's too late. Book an appointment: https://www.airflowexpert.com Airflow Experts City: Old Bridge Address: 21 Hilliard Rd. Website: https://www.airflowexpert.com/ Phone: +1 732 824 8243 Email: gina@airflowexpert.com

Tento rok je to presne 10 rokov od výnimočného úspechu AS Trenčín v slovenskej lige, ktorý má dnes až neuveriteľnú hodnotu. V súčasnosti má klub úplne opačné starosti. S asistentom trénera Petrom Čögleyom sme v 44. epizóde Kam si to kopol? na ŠPORT.sk debatovali aj o Saudskej Arábii.Záver predošlej sezóny Niké ligy mohol skončiť katastrofálne, keďže AS Trenčín musel bojovať o holé prežitie medzi slovenskou ligovou elitou v baráži proti ViOnu Zlaté Moravce. Svoju úlohu nakoniec niekdajší dvojnásobný majster zvládol a najvyššiu súťaž si teda zahrá aj po 15-krát v rade.Žiaľ, výsledky v príprave nenasvedčujú, že by sa fanúšikovia Trenčína mali tešiť na prichádzajúcu sezónu, keďže z piatich prípravných stretnutí nedokázal AS vyhrať ani jedno a celkové skóre dosiahlo hodnotu nepríjemného pomeru 3:14.Mužstvo spod hradu Matúša Čáka sa pripravuje už pod vedením navrátilca na lavičku AS Holanďana Ricarda Moniza, ktorý na tejto pozícii nahradil Ivana Galáda. Ako vyzerá rozpoloženie kádra, jeho stav či samotné ciele Trenčína pred novým ročníkom Niké ligy, ktorý štartuje už počas najbližšieho víkendu, o tom sa futbalový redaktor Ján Jasenka a moderátor Marián Lontoš porozprával v podcaste Kam si to kopol? na ŠPORT.sk s asistentom trénera Petrom Čögleyom.S niekdajším skvelým krajným obrancom sme, okrem iného, podebatovali aj o jeho skúsenostiach v Saudskej Arábii, kde pôsobil pod vedením svojho kamaráta Martina Ševelu v klube Al-Adalah.

Tento rok je to presne 10 rokov od výnimočného úspechu AS Trenčín v slovenskej lige, ktorý má dnes až neuveriteľnú hodnotu. V súčasnosti má klub úplne opačné starosti. S asistentom trénera Petrom Čögleyom sme v 44. epizóde Kam si to kopol? na ŠPORT.sk debatovali aj o Saudskej Arábii.Záver predošlej sezóny Niké ligy mohol skončiť katastrofálne, keďže AS Trenčín musel bojovať o holé prežitie medzi slovenskou ligovou elitou v baráži proti ViOnu Zlaté Moravce. Svoju úlohu nakoniec niekdajší dvojnásobný majster zvládol a najvyššiu súťaž si teda zahrá aj po 15-krát v rade.Žiaľ, výsledky v príprave nenasvedčujú, že by sa fanúšikovia Trenčína mali tešiť na prichádzajúcu sezónu, keďže z piatich prípravných stretnutí nedokázal AS vyhrať ani jedno a celkové skóre dosiahlo hodnotu nepríjemného pomeru 3:14.Mužstvo spod hradu Matúša Čáka sa pripravuje už pod vedením navrátilca na lavičku AS Holanďana Ricarda Moniza, ktorý na tejto pozícii nahradil Ivana Galáda. Ako vyzerá rozpoloženie kádra, jeho stav či samotné ciele Trenčína pred novým ročníkom Niké ligy, ktorý štartuje už počas najbližšieho víkendu, o tom sa futbalový redaktor Ján Jasenka a moderátor Marián Lontoš porozprával v podcaste Kam si to kopol? na ŠPORT.sk s asistentom trénera Petrom Čögleyom.S niekdajším skvelým krajným obrancom sme, okrem iného, podebatovali aj o jeho skúsenostiach v Saudskej Arábii, kde pôsobil pod vedením svojho kamaráta Martina Ševelu v klube Al-Adalah.

On this week's episode of the Joy of Football Podcast, Martin and Neil revisit an amazing week in football. During which Martin shouted his famous “Aguerooooo”, and only a few days later commented Chelsea's first ever Champions League win… with Neil only 8ft in front of him!From Aguero, to Drogbaaaaa, this episode takes us inside that week, the dramatic final day, behind the scenes for Neil in the Chelsea hotel in Munich, UEFA confiscating his tapes, his son hugging Roman Abramovich, and so much more!May of 2012… what a time. [CHAPTERS]00:00 INTRO01:44 Did Martin know what he was going to say in celebration?04:13 When did Martin Tyler realise how big the Agüero moment would be?06:12 Seeing the Executive Chairman of the Premier league straight after the game!07:43 "Now I listen to it as if its another person doing it" 08:06 "Did you do any preparation for the UCL final SIX days later?" 09:30 Mark Hughes claims it was the nosiest moment in a football ground he's ever heard!10:54 Problems in the Chelsea squad leading up to the final11:35 Neil Barnetts journey for ChelseaTV to Lille to film with Joe Cole!12:57 Joe Cole told Neil Barnett that Eden Hazard would sign for Chelsea!13:38 How did Denis Wise save Neil Barnett's day? 15:40 What problems did Bayern Munich have leading up to the final?17:26 The surprising role of Ryan Bertrand 19:03 Nights out in Munich (John Terry's dad + Babayaro charging drinks to UEFA!)23:03 Jody Morris broke the news to Neil that Ryan Bertrand was starting23:53 Shouting for Ruud Gullit to get an interview!26:10 How did the actual game go? 27:40 What moment in the game made Martin Tyler feel lucky/proud?29:30 Neil's reaction to Drogba's equaliser30:49 "Give me Didier over Thierry Henry any day" 32:03 What did Drogba tell Neil privately after the game? 32:40 Robben's story about his friendship with Petr Cech!36:07 The dramatic penalty shootout!38:17 Neil and Martin's hug WHILST still commentating (+Gary Nevilles handshake) 39:38 Martin's moment of reflection after the historic week41:46 UEFA confiscated Neil's exclusive tapes!44:57 Neil went to the team afterparty with his son! (Hugging Roman Abramovic)47:26 Presenting on the open bus parade in London!49:09 How Neil got in trouble with his wife!49:51 "That truly was the most extraordinary week" 51:57 "Being entertained became more important than winning...So lucky Chelsea signed Hazard"52:16 Martin Tyler and Neil's invite to Eden Hazard to come on the podcast53:36 WHERE TO FIND US!Join Neil Barnett (former Chelsea touch-liner announce and football journalist) alongside the voice of the Premier League Martin Tyler in celebrating the greatest addiction in the World!Hosted by The Revive Lounge Ltd UCsdye1hUxP4xhgBx9zvuSjgSubscribe to https://youtube.com/@TheReviveLounge?si=L5ddzrJrtSmErtJ5Support the Pod https://patreon.com/TheJoysofFootballPodcast?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLinkRead us on Substack https://martintylerandneilbarnett.substack.com/Follow our Twitter https://x.com/TheJOFFollow our Tik Tok https://www.tiktok.com/@joy_of_football_pod?is_from_webapp=1&sender_device=pcFollow our Instagram https://https://www.instagram.com/joy_of_football_pod/Contact us via: therevivelounge@gmail.comMusic by Arron Clague - https://www.instagram.com/arronclague?igsh=aHg1bjQ3OHpmaXIzIntro Sequence by Wellong Sadewo (wells.illustration): https://www.instagram.com/wells.illustration/Send us a textSupport the show

In this episode of the Women in Safety podcast, Alanna Ball explores the pressing issue of burnout in the health and safety profession. Drawing from a recent article by Amanda Lyras, a partner at Clayton Utz, Alanna explores the psychosocial risks associated with long working hours and the cultural shift needed to address them.Alanna shares her personal journey of overcoming burnout and the importance of creating a balanced work environment. She discusses practical strategies like time blocking and self-care, urging listeners to reflect on their own work habits and the systemic issues within their organisations.Key takeaways:- Recognising the signs of burnout and fatigue in yourself and your team. - Implementing practical controls to manage workloads and track working hours. - Encouraging open conversations about overwork and its impact on health and safety.Join Alanna and the Women in Safety community as they empower each other to thrive in their careers without sacrificing well-being. Don't miss this insightful episode that challenges the hustle culture and promotes a healthier approach to work.Got questions?Connect with us on Instagram - https://www.instagram.com/womeninsafety/ Email us -  admin@womeninsafety.net Sign up for the newsletter - https://www.womeninsafety.net/ Don't forget to share this episode with your network and help us spread the word about the incredible work being done in the health and safety profession!Be sure to hit follow on Spotify or the + on Apple Podcasts to get the latest episodes.If you share this episode on your socials, be sure to tag @womeninsafety

Hometown Radio 07/17/25 5p: SLO Fire chief Todd Tuggle discusses the new Fire Hazard Zones

DLACZEGO NIE CZUŁ JUŻ ZAUFANIA W KATOWICACH ORAZ JAK WIDZI SWOJĄ ROLĘ W KOLEJNYM SEZONIE W WIDZEWIE. CO MYŚLI O SPROWADZENIU DRUGIEGO NAPASTNIKA I CO POTRZEBUJĘ, ABY STRZELAĆ WIĘCEJ GOLI? PO WIĘCEJ ROZWIŃ OPIS_______________________________________________________________⭐️ PARTNEREM KANAŁU JEST LEGALNY POLSKI BUKMACHER LEBULL

Halftime Heroes, hosted by Adam Kelly, Neil Craig, Pete Susovich, Chris Gamble and Spook Harris. Special Guest Panelist - Matt Haverfield, Snr Coach, Tyabb FNC. Coaches Corner - Joining The Commish under the cone of silence is 8 year Coaching veteran Matt Haverfield. Matt drops a bomb under the cone.......what's happening I hear you say, it's a must listen. HH Selection Table:Div 1 - Mt. Eliza FNC v Dromana FNC.Div 2 - Pearcdale FNC V Frankston Bombers FNC. Sus's Pallets - The Heroes went down to support their great mate and regular Chris Gamble, Snr Coach of Somy FNC. Sus nearly killed a kid and blew out a knee at the same time when he tripped down the steps in front of the rooms.....Devon Meadows, you need Hazard tape on those steps, we nearly lost the Cheif!! Spooks Soap Box - Alllll Cafes, you're on notice, when making a long black put the right effing amount of cold water in it so Spook doesnt burn his mouth, like Molten Lava it is!!! Halftime Heroes Website Halftime Heroes Facebook PageSee omnystudio.com/listener for privacy information.

Long hours, heavy caseloads, high stakes—such is the modern trial practice. But when lawyers represent survivors of violent or traumatic incidents, they often experience next-level stress caused by empathetic engagement. In this episode, UNT Dallas College of Law professor and JAMS neutral mediator, arbitrator, and special master Angela Downes introduces listeners to vicarious trauma and its effects on body and mind, how vicarious trauma differs from burnout, and how to recognize compassion fatigue in yourself and your colleagues. Most importantly, Professor Downes discusses effective stress-management strategies that would benefit anyone with a busy trial practice. Topics3:46    What is vicarious trauma?   4:15    Lawyers, vicarious trauma, and burnout7:31    Indicators of vicarious trauma and getting support15:49  How firms can help17:40  Self-care strategies27:55  ABA studies on lawyer stress31:02  More strategies35:09  Recognizing vicarious trauma in others38:20  New generation attunement to wellness40:24 Sign-off questions Quote“So many of us are defined by the work that we do, and we are more than that. We are more than just … being attorneys and counselors. Although it's a big part of us, there are so many sides to what we do and who we are as people.” Professor Angela DownesResourcesProfessor Angela Downes (bio)NITA Women in Trial (program)Stress, Drink, Leave (article)ABA Profile of the Legal Profession (article)ABA Directory of Legal Assistance Programs (resource)

PREZES ARKI GDYNIA SZCZERZE O FINANSACH, CZY KLUB JEST GOTOWY NA EKSTRAKLASE, POWROCIE CZUBAKA, SZCZEGÓŁACH BUDŻETU, NEGOCJACJACH Z PIŁKARZAMI, PLANACH NA PRZYSZŁOŚĆ W GDYNI, ALE PO WIĘCEJ ROZWIŃ OPIS_______________________________________________________________⭐️ PARTNEREM KANAŁU JEST LEGALNY POLSKI BUKMACHER LEBULL

How can a day at the ballpark teach you everything you need to know about safety? In this episode of What's the Hazard, host Doug Fletcher sits down with Marc McClure of Riskill to explore how America's favorite pastime mirrors the fundamentals of workplace safety.From OSHA risk matrices to hazard recognition in the stands, Marc breaks down how he's revolutionizing safety training—by taking it to the baseball field. Learn about “can of corn” hazards, the impact of tempo, and why risk perception is everything. Plus, hear hilarious and insightful stories that make this episode both educational and entertaining.

We are just at the start of hurricane season, and we're already seeing the danger and tragedy brought on by storms. There's another cost that gets much less attention, but it's a gamble everyone in the path of a storm has to make.Today on the show, we examine the decision on whether or not to evacuate from an oncoming disaster. Based on the digital story: 1 reason people don't evacuate for hurricanes? Rising costs, and they're getting pricierRelated episodes:Hazard maps: The curse of knowledgeUnintended Consequences, Hidden DeathsThe brewing recovery in Western North CarolinaFor sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Parents are bombarded with and overwhelmed by complex cultural, environmental, economic and political issues that impact their parenting skills, choices and confidence. By approaching various parenting challenges and questions from a science and social justice lens and parenting based on values, we can be more aware of the systemic forces that harm kids, differentiate what we can and cannot control, and build more fulfilling relationships with our children. Tune in to this episode to learn about: ●        the connection between science and justice ●        science curiosity vs. science literacy ●        values-based parenting ●        food-related topics including: o   infant formula o   clean eating o   MSG o   PFAS/forever chemicals o   Fat phobia ●        Hazard vs risk ●        The origins of and history behind BMI ●        Resources and related episodes Full shownotes, transcript and resources: https://soundbitesrd.com/290             

In this episode of The Poultry Nutrition Blackbelt Podcast, Dr. Cangliang Shen from West Virginia University explores how microbial contamination in poultry poses emerging challenges for food safety. He discusses the use of surrogate bacteria, thermal processing techniques, and sanitation protocols in real-world poultry feed operations. Listen now on all major platforms!"We find that temperature up to 80°C can reach a three log reduction for the efficiency, which gives us hints for developing sanitation procedures and hazard plans for local industry facilities."Meet the guest: Dr. Cangliang Shen earned his Ph.D. in Meat Science and Food Safety from Colorado State University, with earlier training in Veterinary Medicine. He is currently a Professor and Extension Specialist at West Virginia University, focusing on improving poultry meat and feed safety through microbiological research and hazard planning.Click here to read the full research article!Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:04) Introduction(03:27) Current research focus(04:38) Temperature thresholds effectiveness(06:50) Ingredient impact on safety(09:44) Hazard planning insights(13:11) Future research directions(14:55) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like:* Kemin* Kerry- Poultry Science Association- Anitox- BASF

There are expectations the Government continuing to step in to cover natural hazard costs for homeowners could create a moral hazard. An independent climate adaptation report reveals annual losses from weather-related events over the next 25 years could increase by a quarter. It warns the later we respond, the more disruptive the adjustment will be. Chair Matt Whineray told Heather du Plessis-Allan the best way forward is for people to understand what they can get and for the Government to move away from buyouts. He says this needs to be done over a period of time so the market has time to adjust and so people have fair warning and an opportunity to respond. LISTEN ABOVE See omnystudio.com/listener for privacy information.

VROOM VROOM!

 January 5-11, 1985 After a long time coming Ken welcomes podcast inovater, writer, video game expert and all around brother from another mother Glenn Rubenstein. Ken and Glenn discuss strange hobbies they explored during COVID, The Ratings Game with Danny DeVito, Double Trouble, It's Your Move, twins, not remember who is who, hunting down theme songs, testifying against Nintendo, The Game Genie, Galoob, holy grail toys, Inspector Gadget, PXL2000, Made for-TV Movies, The Mod Squad, recognizing the false sense of danger that sensationalized news stories have created, mentioning Bill Campbell pre-Rocketeer, being incredibly angry that the Love Skills VHS tape isn't sexy or instructional enough, shaming adults for renting adult films, CES, meeting John Eric Hexum as a kid, Voyagers, writing a heist movie, freeing digital archives, not living in the streaming future we were promised, getting into Spanish language pop music, Menudo, Dance Fever, the GOOD David Horowitz, Fight Back, avoiding Sam episodes of Diff'rent Strokes, meeting Dana Plato, Kids Inc, removing the adult references from songs covered by Kids Inc, having a crush on Bess Armstrong, loving a Catherine Hicks type, certain actors you always confuse, the TV version of a certain movie actor, buying and resurrecting defunct brands, L.A. Gear fantasies, Phoebe Cates in Lace, Revenge of the Nerds, Just One of the Guys, Jeff Franklin's James Brown obsession, sequel TV series, Michael Keaton, Savage Steve Holland, Jason Bateman, LA Law, shows that feel like work to watch, how somebody being a good podcast guest can make you enjoy their work, Night Court, the versatility of Fischer Stevens and Vincent DeNofrio, Jeff Altman in The Dukes of Hazard, guys an executive clearly loved, when Webster was the victim of a house invasion, Cheers, visiting the set of your favorite show, and tips for interviewing celebs. 

Jase coincidentally becomes the star of Bella's impromptu commercial with back-to-back wins—and Willie misses the shoot entirely, even though it's in his own yard. The guys wrestle with living lives that reflect the answer to whether Jesus is just a man—or is he God? Jesus redefines power and flips the world's expectations of kingship, and Zach challenges listeners to think beyond transactional faith and step into a relationship that reflects the intimacy between Jesus and the Father. In this episode: John 10; Deuteronomy 6, verse 4; John 4, verse 23; John 11, verses 11–13; 2 Peter 1, verse 4; Revelation 14, verses 1–4 “Unashamed” Episode 1121 is sponsored by: https://andrewandtodd.com or call 888-888-1172 — These guys are the real deal. Get trusted mortgage guidance and expertise from someone who shares your values! Listen to Not Yet Now with Zach Dasher on Apple, Spotify, iHeart, or anywhere you get podcasts. — Learn more about your ad choices. Visit megaphone.fm/adchoices

Kim covers breaking political news for Kentucky, and shares the upcoming "Good Trouble Lives ON" mass mobilizations and protests for voting rights. She also has a great conversation with fellow progressive news collaborator, Bruce Maples of Forward Kentucky about the big news out of DC and what we should call the gut-punch to Kentucky that is the Trump MAGA budget reconciliation package.#ColonelsOfTruthNEWS OF THE WEAK:https://www.insidehighered.com/news/government/politics-elections/2025/06/20/after-texas-doj-targets-kentuckys-state-tuitionINTERVIEW: Bruce Maples, Forward Kentuckyhttps://forwardky.com/CALL TO ACTION: Good Trouble Lives On!On July 17, the 5th anniversary of Congressman John Lewis's passing, we're taking action across the country to defend our democracy and carry forward his legacy of Good Trouble. Join us for a national day of nonviolent action as we rally, march, host teach-ins, press conferences, and vigils to demand that Congress fight back and protect our freedom to vote!Events are popping up all across the state, from Hazard to Shepherdsville, Frankfort to Beaver Dam, Lexington to Louisville. Find the closest one for you right here:https://www.mobilize.us/john-lewis-actions/#ProgressKentucky - #ColonelsOfTruthJoin us! http://progressky.org/Support us! https://secure.actblue.com/donate/progresskyLive Wednesdays at 7pm on Facebook https://www.facebook.com/progressky/live/and on YouTube http://bit.ly/progress_kyListen as a podcast right here, or wherever you get your pods: https://tr.ee/PsdiXaFylKFacebook - ⁠@progressky⁠ Instagram - ⁠@progress_ky⁠ Bluesky - ⁠https://bsky.app/profile/progressky.bsky.socialhttps://linktr.ee/progresskyEpisode 217 was produced by Parker Williams, Co-Chair, ProKY Coms CommitteeTheme music from the amazing Nato - hear more at http://www.NatoSongs.com

A confirmed measles outbreak in Central Kentucky, the Kentucky connection to recent SCOTUS rulings, remembering an icon in horse racing, thousands show up to see the General Lee jump a Kentucky fountain, and a look back at the history of Frankfort.

On Thursday, June 26th, 2025, Conley Owens debated "Hazard's Ghost" (on x.com as @WhosDude) about charging for Christian conferences. sellingjesus.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠thedoreanprinciple.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠copy.church

Today on the Woody and Wilcox Show: Things stuck in your body; Fun With Golf Audio; Woman claims she was not allowed on a ride at Disney because of what she was wearing; The Ataris released an album with ashes of a band member's father in the vinyl; Dukes of Hazard actor has passed away; Woody's Tom Wopat story; Pilots are encouraged to fart in front of each other; Chelsea and a listener have dreams about Wilcox's death; And more!

Acey Baby is BACK on the Limitless Wrestling Podcast! Josh & Randy are joined by the former Limitless Wrestling World Champion to talk his weight loss of 200+lbs, Wrestling Day @ Long Creek Youth Development, his road ahead in wrestling + much more! We also dive into a full preview of Saturday's BEERLY LEGAL which has been moved from Portland, ME to our home base at the Yarmouth Amvets Hall due to weather! ON THE CARD: - Limitless Championship: Channing Thomas vs. Gabby Forza - VLC Qualifier: Bear Bronson vs. Alec Price - VLC Qualifier: Aaron Rourke vs. Zak Patterson - VLC Qualifier: Aiden Aggro w/ J-Heru vs. Milo Mirra - Scotty 2 Hotty, Keagan Garland & Ace Romero vs. Swipe Right + Jose Zamora - 23 HAZARD vs. Seabass Finn - Dezmond Cole vs. Anthony Greene

Starvation Heights comes to an end but not before Muriel feeds us all the final nasty/tasty tidbits. This is it, the conclusion of our trilogy. Check out Part 1 and Part 2 on YouTube or wherever you get your audio. Part 3 video up on Spotify and YouTube.Support our show and unlock tons of exclusive episodes on Patreon or Spotify.Hit us up on YouTube.Hit us up on Instagram.Hit us up on TikTok.Subscribe to our Free Substack to get new episodes emailed to you directly.Feel free to buy us a beer, or coffee, or pizza, or anything. Many thanks!Researched, written and hosted by Muriel.Produced and co-hosted by Nick.Info: www.murielsmurders.com/support

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

A lil ol' cinnamon roll of a heroine enters the chat. Time for a real superwoman to roll up her sleeves and save Dora. Please go back and listen to Part One to catch up on just who the hell "Dr." Linda Hazard is and just how sadistic her "expertise" on fasting gets. Part Two of Three. Support our show and unlock tons of exclusive episodes on Patreon or Spotify.Hit us up on YouTube.Hit us up on Instagram.Hit us up on TikTok.Subscribe to our Free Substack to get new episodes emailed to you directly.Feel free to buy us a beer, or coffee, or pizza, or anything. Many thanks!Researched, written and hosted by Muriel.Produced and co-hosted by Nick.Info: www.murielsmurders.com

We speak with podiatrist Liam McManus and RW columnist Sophie Raworth about some of the potential risks of wearing supershoes – and what runners can do to mitigate this. Join Runner's World Club today: https://www.runnersworld.com/uk/podcastoffer Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode of Heartbeat of Humanity is the fourth and last episode in a mini-series about the mental health of children and young adults in the contexts of emergencies or conflict with child and adolescent psychiatrist Brett McDermott.In this episode, MHPSS Adviser Arz Stephan talks to Brett  about who among children  and adolescents - or people in general - need further support following a natural hazard.Brett is an Australian child and adolescent psychiatrist. He is head of Tasmania's Child and Adolescent Mental Health Service and professor at the University of Tasmania. Brett has led several post-disaster programs in Australia to better support young people experiencing the trauma of floods, cyclones, bushfires and storms. His approach has influenced post-disaster interventions globally.Brett is currently a visiting scholar at the MHPSS hub. 

Old timey doctor - the lady version! A story so right for this podcast it's almost impossible to believe it's true. But it is. And sickening too. Plus it takes place in and around Seattle, pretty much exactly where Nick and Muriel spent their childhood and early adulthood. Also, her name truly, actually, is Dr. Hazard. RIPs no doubt. Full video of this episode up now on YouTube.Support our show and unlock tons of exclusive episodes on Patreon or Spotify.Hit us up on YouTube.Hit us up on Instagram.Hit us up on TikTok.Subscribe to our Free Substack to get new episodes emailed to you directly.Feel free to buy us a beer, or coffee, or pizza, or anything. Many thanks!Researched, written and hosted by Muriel.Produced and co-hosted by Nick.Info: www.murielsmurders.com

On today's show we are talking about new dangers in apartment buildings that have not been fully handled in the design of buildings or the building code. Certain metals produce their own fuel once ignited. You probably have done the science experiment of lighting a piece of magnesium wire on fire. Once lit, you can put this piece of burning wire into a tub of water and it will keep burning. The conventional wisdom in fire fighting is that if you have a fire, then the fastest way to put it out is to remove its source of oxygen. But what happens when the fire produces its own oxygen and the chemical reaction continues no matter what you do? Have you ever wondered why fireworks don't go out even if it's raining? Once a firework is lit, it will continue to burn until all of the fuel is expended. Now imagine if the fire is in the underground garage in your apartment building, or perhaps in the bicycle storage room next to the lobby of your building. Those electric bicycles are now a new type of fire hazard that didn't exist a few years ago. The electric vehicles are a new type of fire hazard that didn't exist a few years ago. When I look at the risks in a building, I believe that the bicycle room represents an equal if not a greater fire risk than the garage. In many cases, charging is being retrofitted into buildings that were never designed to have electric vehicles. This is something that you as a building owner need to become educated about and take real steps to mitigate that risk. --------------**Real Estate Espresso Podcast:** Spotify: [The Real Estate Espresso Podcast](https://open.spotify.com/show/3GvtwRmTq4r3es8cbw8jW0?si=c75ea506a6694ef1)   iTunes: [The Real Estate Espresso Podcast](https://podcasts.apple.com/ca/podcast/the-real-estate-espresso-podcast/id1340482613)   Website: [www.victorjm.com](http://www.victorjm.com)   LinkedIn: [Victor Menasce](http://www.linkedin.com/in/vmenasce)   YouTube: [The Real Estate Espresso Podcast](http://www.youtube.com/@victorjmenasce6734)   Facebook: [www.facebook.com/realestateespresso](http://www.facebook.com/realestateespresso)   Email: [podcast@victorjm.com](mailto:podcast@victorjm.com)  **Y Street Capital:** Website: [www.ystreetcapital.com](http://www.ystreetcapital.com)   Facebook: [www.facebook.com/YStreetCapital](https://www.facebook.com/YStreetCapital)   Instagram: [@ystreetcapital](http://www.instagram.com/ystreetcapital)  

In this episode of Heartbeat of Humanity, MHPSS Adviser Arz Stephan talks to Brett McDermott about how parents and caregivers can help children get through the first year after a natural hazard.Brett is an Australian child and adolescent psychiatrist. He is head of Tasmania's Child and Adolescent Mental Health Service and professor at the University of Tasmania. Brett has led several post-disaster programs in Australia to better support young people experiencing the trauma of floods, cyclones, bushfires and storms. His approach has influenced post-disaster interventions globally.Brett is currently a visiting scholar at the MHPSS hub. This episode of Heartbeat of Humanity is the third in a four-episode mini-series about the mental health of children and young adults in the contexts of emergencies or conflict.

Na Ukrajine je to dnes "Kto z koho". Rusko sa vydalo cestou opotrebovávajúcej vojny. V nej zvíťazí ten, kto bude schopný v tomto konflikte vydržať dlhšie. Tá vojnová línia sa dnes vedie medzi imperiálnym Ruskom a Ukrajinou podporovanou našou euroatlantickou civilizáciou. Tvrdí bývalý diplomat Peter Weiss. Podľa neho Rusku ide aj o rozloženie EÚ a NATO a preto je postoj Ficovej vlády iracionálnym hazardom s našimi národnoštátnymi záujmami.Ani druhé kolo priamych Rusko Ukrajinských rokovaní, ktoré sa včera uskutočnilo v Istanbule neprinieslo žiadny posun k ukončeniu ruskej agresie na Ukrajine. Návrhy, ktoré Rusko predložilo sú zjavne pre Ukrajinu neprijateľné a navyše, krátko predtým podnikli Ukrajinci bezprecedentný a úspešný dronový útok na strategické ruské letectvo hlboko v tyle nepriateľa. Táto vojna bude nadlho a bude to - kto z koho, teda či dlhšie vydrží Rusko alebo Ukrajina podporená našou euroatlantickou civilizáciou, hovorí pre Aktuality Nahlas exdiplomat Peter Weiss Zatiaľ čo vojna na Ukrajine nemá konca, slovenská zahraničná politika čoraz viac zapadá do pasce dvojtvárnosti a populistického alibizmu. Na jednej strane sa náš premiér ostentatívne chodí klaňať do Kremľa a vedie prázdne reči o mieri, na strane druhej sa zo Slovenska stáva zbrojárska veľmoc a naša vláda nemá pre našich kľúčových západných spojencov pekného slova. Do sporu sme sa dostali už aj s novým nemeckým kancelárom, ktorý nám pohrozil stopnutím eurofodov. Odpoveďou sú mu reči o fírerovi či volanie po vystúpení z EÚ. Kritika sa skrátka vo vládnej koalícií akosi nenosí. Počúvate Aktuality Nahlas, dnes o aktuálnom vývoji v mierových rokovaniach medzi Ruskom a Ukrajinou, ale aj o čudnej suverenite Ficovej zahraničnej politiky, ktorá podľa kritikov začína zásadne ohrozovať strategické záujmy krajiny. O čo teda Robertovi Ficovi vlastne ide a má ešte pod kontrolou nielen to, čo sa mu v tejto krajine deje, ale i to, aký obraz Slovensko dnes vysiela do sveta? A je niekde v pozadí "hra patriotov" o vyviazaní Slovenska zo zväzku Európskej únie? Témy pre bývalého diplomata a expredsedu SDĽ Petra Weissa.Počúvate Aktuality Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

The Choking Hazard Podcast - Episode 95 - GTA 6 Thoughts, Dad Life, Business Owners & More!More Podcast Content: https://broughy.com/podcastSee all podcast episodes as videos in this playlistContributors[Host] Broughy1322: https://broughy.com[Co-Host] Sugar Free Nos: https://twitch.tv/sugar_free_nos[Co-Host] RDT33: https://twitch.tv/rdt33[Co-Host] Joshimuz: https://twitch.tv/joshimuz[Producer] MBHammer: https://twitch.tv/mbhammerTimestamps0:00:00 - Introduction0:01:49 - GTA VI Trailer 20:11:55 - Broughy's Parenting Report0:20:09 - Nos Owns A Dominos! And A New Car1:00:28 - Josh Hosted A GTAMarathon Event IRL1:24:38 - Twitch Deletes VOD Highlights1:32:42 - Gaming News1:42:49 - Racing Corner1:49:47 - Speedrun CornerPodcast pre-shows & gaming nights are all on https://youtube.com/ChokingHazardGaming

This is May 25th's sermon by Jason Cherry walking through the hazards pictured in Psalm 124 and the sins each address. Jason Cherry is an elder at Trinity Reformed Church, as well as a teacher and lecturer of literature, American history, and economics at Providence Classical School in Huntsville, Alabama. He graduated from Reformed Theological Seminary with an MA in Religion and is the author of the book The Culture of Conversionism and the History of the Altar Call, now available on Amazon. He is husband to Traci, who is proficient at blessing others, and father to Anily and Gaby, who are gifted in the art of laughter. Trinity Reformed Church is a CREC church in Huntsville, AL. seeking to extend and unite the Kingdom in the Huntsville area. Check out our website, Facebook or YouTube!

Thank you so much for listening to the Bob Harden Show, celebrating nearly 14 years broadcasting on the internet. On Tuesday's show, we visit with Florida State Senator Kathleen Passidomo about the current extended legislative session to finalize the state budget. We visit with economics and political columnist Patrick Carroll about questions raised concerning the tariff agreement between the United State and the U.K about food standards. Boo Mortenson and I discuss the threat of “AI” to college education and the return to “blue book” exams. We also visit Linda Harden about the evidence of health hazards created by “5G.” Please join us tomorrow when we visit with Chairman Emeritus of Cato Institute Bob Levy and Professor Andrew Joppa. Access this or past shows at your convenience on my web site, social media platforms or podcast platforms.

⚠️CAUTION⚠️ : King's Crossing!Seattle funny man, filth icon, and Emerald City King's Ball Grand Marquis Chance Hazard joins The Rewind. Let's dive into what drives his comedy, his art, and his overall goofy personality.You better be out there supporting Drag Kings! You can support Chance by clicking on his linktree: https://linktr.ee/ChanceHazardDragAnd support Thumali and Wayward World Studios: https://linktr.ee/waywardworldstudios

Fortune favors the prepared!The Midwest Misfits aren't just a name—they're the real deal. On this episode of What's the Hazard, host Doug Fletcher goes behind the scenes with Nate, Cody, and Ryan to explore why rescue standby, industrial safety assessments, and hands-on confined space training are the future of workplace safety.If you've ever called 911 as your confined space rescue plan—you need to watch this episode.Awesome References:Children's Hospital: https://www.childrensomaha.orgBike With Mike: https://www.bikewithmikeday.com50 Mile March: https://50milemarch.orgReach out to the Misfits!mwmisfits.com(402)-984-8203Cody: cody.brdico@mwmisfits.comRyan: ryan.loewenstein@mwmisfits.comDoug Fletcher can be reached at doug@fletchersafety.comIf you have any topics you'd like Doug to address, feel free to reach out via email or shoot him a message on LinkedIMuch gratitude to our Sponsors and Supporters!Fallowich Construction Services: https://www.fallowichconstruction.comRockford Systems: https://rockfordsystems.com__________________________________This is another Hurrdat Media Production. Hurrdat Media is a podcast network and digital media production company based in Omaha, NE. Find more podcasts on the Hurrdat Media Network by going to HurrdatMedia.com or Hurrdat Media YouTube channel!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Contributor: Jorge Chalit-Hernandez, OMS3 Educational Pearls: Psychedelics are being studied for their therapeutic effects in mental illnesses, including major depressive disorder, post-traumatic stress disorder, anxiety, and many others Classic psychedelics include compounds like psilocybin, LSD, and ayahuasca MDMA and ketamine are often included in psychedelic research, but have a different mechanism of action than the others Their mechanism of action involves agonism of the 5HT2A receptor, among others Given their resurgence, there is an increase in recreational use of these substances A recent study assessed the risks of recreational users developing subsequent psychotic disorders Individuals who visited the ED for hallucinogen use had a greater risk of being diagnosed with a schizophrenia spectrum disorder in the following 3 years Hazard ratio (HR) of 21.32 After adjustment for comorbid substance use and other mental illness, the hazard ratio was 3.53 - still a significant increase compared with the general population They also found an elevated risk for psychedelics when compared to alcohol (HR 4.66) and cannabis (HR 1.47) The study did not assess whether patients received antipsychotics or other treatments in the ED References Lieberman JA. Back to the Future - The Therapeutic Potential of Psychedelic Drugs. N Engl J Med. 2021;384(15):1460-1461. doi:10.1056/NEJMe2102835 Livne O, Shmulewitz D, Walsh C, Hasin DS. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP. Addiction. 2022;117(12):3099-3109. doi:10.1111/add.15987 Myran DT, Pugliese M, Xiao J, et al. Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder. JAMA Psychiatry. 2025;82(2):142-150. doi:10.1001/jamapsychiatry.2024.3532 Summarized & Edited by Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

Arson and more undead threaten the lives of the party as well as some of the town's first settlers. Watch the video here: ⁠https://youtu.be/vr7Ubm60eOQ Join Troy Lavallee, Joe O'Brien, Skid Maher, Matthew Capodicasa, Sydney Amanuel, and Kate Stamas as they tour the country. Get your tickets today at ⁠https://hubs.li/Q03cn8wr0⁠. Access exclusive podcasts, ad-free episodes, and livestreams with a 30-day free trial with code "GCN30" at ⁠jointhenaish.com⁠. For more podcasts and livestreams, visit ⁠https://hubs.li/Q03cmY380⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Get ready for the funkiest episode of The Number Two Show yet! Rafe Williams sits down with Ryan and Pat from the legendary St. Louis funk band Hazard to Ya Booty to talk about their origin story, cosmic funk magic, and the strange connection between comedy and bass playing. Then they light up the studio with two incredible live performances: “Get the Gurney” and “Gimme That” — including the world premiere of their hot new single. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Get ready for the funkiest episode of The Number Two Show yet! Rafe Williams sits down with Ryan and Pat from the legendary St. Louis funk band Hazard to Ya Booty to talk about their origin story, cosmic funk magic, and the strange connection between comedy and bass playing. Then they light up the studio with two incredible live performances: “Get the Gurney” and “Gimme That” — including the world premiere of their hot new single. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The federal government has been tracking the weather for more than 150 years. But the rise of the Internet and big tech have made weather forecasting a more crowded space. Today on the show, the value of an accurate forecast and how the Trump administration's early moves are clouding the government's future forecasting. This piece originally aired in November 2024. Related stories: Hazard maps: The curse of knowledge (Apple / Spotify) Should we invest more in weather forecasting? After a year of deadly weather, cities look to private forecasters to save lives Fact-checking by Sierra Juarez. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy